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Abstract
In current clinical trial development, historical information is receiving more attention as provid-
ing value beyond sample size calculation. Meta-analytic-predictive (MAP) priors and robust MAP
priors have been proposed for prospectively borrowing historical data on a single endpoint. To si-
multaneously synthesize control information from multiple endpoints in confirmatory clinical trials,
we propose to approximate posterior probabilities from a Bayesian hierarchical model and estimate
critical values by deep learning to construct pre-specified decision functions before the trial conduct.
Simulation studies and a case study demonstrate that our method additionally preserves power, and
has a satisfactory performance under prior-data conflict.
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1 Introduction
Historical control data are usually summarized as estimates of parameters needed to calculate the
sample size when designing a traditional Phase III randomized clinical trial (Chow et al., 2007).
This relevant information can be properly borrowed for the current trial to make it more efficient
and ethical, by allowing fewer patients randomized to the control group, or decreasing the total
sample size (Berry et al., 2010; Viele et al., 2014). Some challenges exist in applying this framework
to clinical trials, especially confirmatory studies. While it is always possible to retrospectively use
historical information once the new evidence is available, it is appealing to ensure study integrity
by designing a prospective algorithm for leveraging historical data (Neuenschwander et al., 2010).
Moving beyond the “sweet spot” where the borrowed information and the current data are close, one
needs to properly discount historical information to control the bias and the type I error rates (Viele
et al., 2014).
In the context of a single endpoint, Neuenschwander et al. (2010) proposed a novel meta-analytic-
predictive (MAP) approach to prospectively borrow historical information for the current trial.
Schmidli et al. (2014) further developed an innovative method to approximate the MAP prior by
a mixture of conjugate priors, and therefore the posterior distribution is available in a closed form. A
robust MAP prior is then formulated by adding a weakly informative component to discount historical
data under prior-data conflict (Schmidli et al., 2014). Moving further to confirmatory clinical trials,
most use multiple endpoints to assess the effects of the study drug (Food and Administration, 2017).
A Bayesian hierarchical model is a natural approach to simultaneously synthesize information from
multiple endpoints (Berry et al., 2010). However, taking a trial with binary endpoints as an example,
additional non-trivial work is needed to generalize the MAP framework to approximate the joint
prior of response rates and to investigate whether the resulting multivariate posterior distribution is
available analytically.
As an alternative, we propose a two-stage Deep Neural Networks (DNN) guided algorithm to
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build pre-specified decision functions before initiation of the current trial. At the first stage, we
take advantage of the strong functional representation of DNN to directly approximate the posterior
probabilities and the posterior means from a Bayesian hierarchical model (Goodfellow et al., 2016).
The pre-trained DNN models can be locked in files before initiation of the current trial to ensure study
integrity. To protect the family-wise error rate (FWER) in confirmatory trials, we further construct
another DNN-based algorithm to estimate the critical values in the second stage. After obtaining
results from the new trial, one can instantly compute the posterior probabilities and critical values
needed for hypothesis testing. This process also contributes to power preservation as compared with
a typical practice of choosing a constant critical value in order to control the maximum simulated
type I error rate within a subset of the null space. Simulations show that our method has relatively
small bias and mean squared error (MSE) under prior-data conflict by properly discounting prior
information.
The remainder of this article is organized as follows. In Section 2, we introduce a Bayesian
hierarchical model on control data from several historical studies. Next we propose a DNN-based
algorithm to approximate the posterior probabilities and critical values with controlled FWER to
build pre-specified decision functions in Section 3. Simulations in Section 4 and a case study in Section
5 are conducted to evaluate the performance of our method. Concluding remarks are provided in
Section 6.
2 A Bayesian hierarchical model on historical control data
Consider a two-group randomized controlled clinical trial with I (I ≥ 2) endpoints to study the
efficacy of a treatment versus placebo. We consider a setup of I = 2 binary endpoints for illustration,
but our method can be readily generalized to I > 2 endpoints and other types of endpoints. Denote
R
(t)
i,0 as the number of responders in the current treatment group for endpoint i, where i ∈ {1, · · · , I},
and n
(t)
0 as the total number of subjects from the treatment arm in the current trial. For each
endpoint i, a beta conjugate prior is assumed on the binomial sampling distribution with rate ψ
(t)
i,0 ,
R
(t)
i,0 ∼ Binomial
{
n
(t)
0 , ψ
(t)
i,0
}
, ψ
(t)
i,0 ∼ Beta(ai, bi), i = 1, · · · , I. (1)
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The control data are available in the current trial and J historical studies. The corresponding
notations are denoted as R
(c)
i,j and n
(c)
j , where j = 0 indicates the current trial, j ∈ {1, · · · , J} is
the index of historical study j, and i ∈ {1, · · · , I} refers to endpoint i. We consider the following
Bayesian hierarchical model on the control data (Neuenschwander et al., 2010; Schmidli et al., 2014),
R
(c)
i,j ∼ Binomial
{
n
(c)
j , ψ
(c)
i,j
}
, µi,j = logit
{
ψ
(c)
i,j
}
, µj ∼MVN(θ,Σ), (2)
where µj = (µ1,j, · · · , µI,j), for i ∈ {1, · · · , I}, j ∈ {0, 1, · · · , J}, and MVN(θ,Σ) denotes a
multivariate normal distribution with mean vector θ and variance-covariance matrix Σ. A vague
prior is assumed on θ, and an InverseWishart(Σ0, k) prior is assigned to the variance-covariance
matrix Σ with positive definite I × I matrix Σ0 and degrees of freedom k ≥ I. The expecta-
tion of a Wishart(Σ0, k) is k (Σ0)
−1, and therefore Σ0/k is a prior guess for Σ. We use DH =[
R
(c)
i,j , n
(c)
j , i ∈ {1, · · · , I} , j ∈ {1, · · · , J}
]
to denote control information in J historical studies, and
DN =
[
R
(c)
i,0 , n
(c)
0 , R
(t)
i,0, n
(t)
0 , i ∈ {1, · · · , I}
]
as data in the current new trial.
Our quantity of interest is the posterior probability of observing a promising treatment effect in
the current trial,
Si = Pr
{
ψ
(t)
i,0 − ψ(c)i,0 > θi
∣∣∣DH ,DN} , i = 1, · · · , I, (3)
where θi is a pre-specified constant for endpoint i. The decision function of rejecting the null hy-
pothesis pertaining to endpoint i is if Si > c˜i. The computation of c˜i is studied in the next section
to control the family-wise error rate (FWER) at a nominal level α. We denote S = (S1, · · · , SI) as
a vector of those posterior probabilities.
Due to the hierarchical structure (2), the computation of S in (3) usually requires the Markov
chain Monte Carlo (MCMC) method (Berry et al., 2010). However, it is appealing to build a prospec-
tive algorithm before conducting the current new trial to ensure the study integrity. In studies with a
single binary endpoint (I = 1), Schmidli et al. (2014) proposed a novel approach by approximating the
Meta Analytic Predictive (MAP) prior p
{
ψ
(c)
i,0 |DH
}
with a mixture of beta distributions, and hence
the posterior distribution p
{
ψ
(c)
i,0 |DH ,DN
}
becomes a weighted average of beta distributions. In the
context of multiple endpoints (I ≥ 2), a Bayesian hierarchical model in (2) is a natural approach
to simultaneously synthesize control information (Berry et al., 2010). Even if one can utilize several
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base distributions to approximate the multivariate prior p
{
ψ
(c)
0 |DH
}
, where ψ
(c)
0 =
{
ψ
(c)
1,0, · · · , ψ(c)I,0
}
,
the joint posterior probability S does not necessarily have an analytic closed form.
As an alternative, we propose to directly approximate S based on observed historical data DH
and varying new trial data DN by deep neural networks (DNN) in the study design stage. After
collecting results from the current trial, one can instantly compute S and conduct downstream
hypothesis testing based on this pre-specified approximation function.
3 A DNN-based historical borrowing framework
In this section, we first provide a short review on DNN in Section 3.1, and then introduce our DNN
guided historical borrowing framework by approximating the posterior distribution of S in Section
3.2 and modeling the critical values in Section 3.3.
3.1 Review on DNN
Deep learning is a specific subfield of machine learning as a new take on learning representations
from data with successive layers (Chollet and Allaire, 2018). A major application of Deep Neural
Networks (DNN) is to approximate some functions with input data (Goodfellow et al., 2016). DNN
defines a mapping function S = F (M ;φ) and learns the value of parameters φ that result in the
best function approximation of output label S based on input data M , where φ denotes a stack of
all weights and bias parameters in the DNN. For example in Figure 1, the left input M of dimension
4 is transfered by 2 hidden layers to predict a 2-dimensional output S on the right.
Typically, training a DNN involves the following four components: layers, input data and cor-
responding output labels, loss function, and optimizer (Chollet and Allaire, 2018). To avoid the
potential over-fitting, cross-validation is commonly used to select the architecture from a pool of
candidates (Goodfellow et al., 2016). The loss function measures how well the fitted DNN F (M ; “φ)
approximates the objective function S. The mean squared error (MSE) loss can be utilized if S is
continuous. The optimizer determines how the network will be updated based on the loss function.
It usually implements a specific variant of the stochastic gradient descent (SGD) algorithm; for ex-
ample, RMSProp (Hinton et al., 2012) has been shown to be an effective and practical optimization
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Figure 1: A Deep Neural Network with two hidden layers.
algorithm for DNN (Goodfellow et al., 2016).
3.2 Posterior probabilities approximation
We denote R
(c)
i =
{
R
(c)
i,1 , · · · , R(c)i,J
}
as a stack of numbers of responders in all historical studies J for
endpoint i, i = 1, · · · , I, and further denote R(c)H =
{
R
(c)
1 , · · · ,R(c)I
}
. Corresponding notations are
R
(c)
N =
{
R
(c)
1,0, · · · , R(c)I,0
}
for the current control group, and R
(t)
N =
{
R
(t)
1,0, · · · , R(t)I,0
}
for the current
treatment arm. The subscript ”H” refers to historical data, while ”N” corresponds to new trial data.
We consider P(c)i as a parameter space covering ψ(c)i,j for endpoint i in all J historical studies and ψ(c)i,0
in the current study. For example, P(c)i =
{
ψ
(c)
i : ψ
(c)
i ∈ (0.1, 0.5)
}
indicates that the control response
rate for endpoint i in all historical studies and the current study ranges from 0.1 to 0.5. It can be
set wider as needed. Similarly, Ti is the parameter space of the treatment effect for endpoint i.
In Algorithm 1, we utilize DNN to construct a mapping function FS(M ; “φ) to predict S in (3)
based on input data M , where M =
{
R
(c)
N ,R
(t)
N
}
and “φ are the estimated parameters in DNN. In
Step 2, we perform cross-validation to select a proper DNN structure. By increasing the number of
layers and number of nodes in DNN, the empirical MSE from the training dataset usually decreases,
but the validation MSE may increase. Then we implement certain regulation approaches, for example
dropout techniques, on the over-saturated DNN structure to decrease validation MSE while keeping
the training MSE below a certain tolerance, for example 10−3. Several structures around this sub-
optimal structure are added to the candidate pool for cross-validation. The final DNN structure is
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selected as the one with the smallest validation error and is utilized in Step 3 to get the predictive
DNN “S = FS(M ; “φ).
We consider a setup where samples size
{
n
(c)
0 , n
(c)
1 , · · · , n(c)J , n(t)0
}
and historical data R
(c)
H are
constants. Therefore, the input data M =
{
R
(c)
N ,R
(t)
N
}
for DNN only contains the number of
responders in the current trial. When there are I = 2 endpoints, M has 4 elements and S has 2
elements as shown in Figure 1. As a generalization, one can build a more general DNN function
to accommodate varying sample size and varying historical data. Similarly, we train another DNN
FP
[
R
(c)
N ;
“φP ] to approximate the posterior means of control response rates [ψ(c)1,0, · · · , ψ(c)I,0]. Note
that only the numbers of control responders R
(c)
N are included as covariates, because the treatment
and control group are assumed to be independent by models (1) and (2).
Algorithm 1 Train a DNN FS(M ; “φ) to approximate the posterior distributions S
1. Construct a training dataset for the DNN of size B. In each training data b, uniformly draw
ψ
(c)
i,0 from P(c)i , ∆i,0 from Ti and set ψ(t)i,0 = ψ(c)i,0 + ∆i,0, for i = 1, · · · , I. The training input
data M =
[
R
(c)
N ,R
(t)
N
]
is further simulated from binomial distributions with their corresponding
response rates. The output label S in (3) is computed based on Section 2.
2. Perform cross-validation on several candidate DNN structures to select one with the smallest
validation error for final fitting.
3. Train a DNN to build an approximating function “S = FS(M ; “φ) to predict S based on data
M , where “φ are the estimated parameters in the DNN.
3.3 FWER control in the strong sense
In this section, we discuss how to compute the critical value c˜i in the decision rule Si > c˜i of rejecting
the null hypothesis pertaining to endpoint i to strongly control FWER at a nominal level α.
Family-wise error rate (FWER) is the probability of rejecting at least one true null hypothesis.
FWER is said to be controlled at level α in the strong sense if it does not exceed α under any
configuration of true and false hypotheses (Bretz et al., 2016). Define H1 and H2 as the single null
hypotheses where only endpoint 1 or 2 has no treatment effect, and H12 as the global null hypothesis
where neither endpoints have treatment effects. In the context of I = 2 endpoints, we need to control
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the following three erroneous probabilities,
Pr
ß
S1 > c1
∣∣∣∣H1™ ≤ α, H1 : ψ(c)1,0 = ψ(t)1,0, ψ(c)2,0 < ψ(t)2,0 (4)
Pr
ß
S2 > c2
∣∣∣∣H2™ ≤ α, H2 : ψ(c)2,0 = ψ(t)2,0, ψ(c)1,0 < ψ(t)1,0 (5)
Pr
ß
(S1 > c12) ∪ (S2 > c12)
∣∣∣∣H12™ ≤ α, H12 : ψ(c)1,0 = ψ(t)1,0, ψ(c)2,0 = ψ(t)2,0 (6)
where c1 is the critical value to control error rate under H1, c2 for H2, and c12 for H12.
In Algorithm 2, we train three DNNs to estimate these three critical values: c1, c2 and c12. Taking
H1 in (4) as an example, we define ψ
(c,t)
1,0 as the common value of ψ
(c)
1,0 and ψ
(t)
1,0 under H1. The training
input data is denoted as M 1 =
{
ψ
(c,t)
1,0 , ψ
(c)
2,0,∆2,0
}
. In Step 1, we simulate B1 varying M 1’s from
parameter spaces to get the training input data. Given each training feature M 1, we then simulate
B′1 samples under H1 and utilize the DNN obtained from Algorithm 1 to calculate their posterior
probabilities at “S = FS(M ; “φ). The critical value c1 is empirically computed as the upper α quantile
of “S1 in “S to satisfy (4). We further train a DNN to obtain a mapping function ĉ1 = F1(M 1; “φ1) to
predict c1 based on M 1. Step 2 constructs ĉ2 = F2(M 2; “φ2) under H2 in (5), and Step 3 computes
ĉ12 = F12(M 12; “φ12) under H12 in (6).
Once observed data are obtained, we estimate M 1 =
{
ψ
(c,t)
1,0 , ψ
(c)
2,0,∆2,0
}
by their empirical coun-
terparts M ′1 =
ï{
R
(c)
1,0 +R
(t)
1,0
}
/
{
n
(c)
0 + n
(t)
0
}
, R
(c)
2,0/n
(c)
0 , R
(t)
2,0/n
(t)
0 − R(c)2,0/n(c)0
ò
under H1 at Step 4.
Utilizing the trained DNN from Step 1, we get ĉ1 = F1(M
′
1;
“φ1). The critical value ĉ2 and ĉ12 are
computed in similar fashion. Since the strong control of FWER is under all configurations of true
and false null hypotheses specified in (4), (5) and (6), we set c˜1 = max(ĉ1, ĉ12) for rejecting null
hypothesis H1 with the decision function S1 > c˜1, and correspondingly c˜2 = max(ĉ2, ĉ12) for H2 at
Step 7. This is analogous to the closure principle of handling multiplicity issues, where the rejection
of a particular elementary hypothesis requires the rejection of all intersection hypotheses containing
it (Tamhane and Gou, 2018).
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Algorithm 2 Approximate the critical values to protect FWER in the strong sense
Train three DNNs to estimate the critical values
1. For H1 in (4), simulate training input data M 1 =
{
ψ
(c,t)
1,0 , ψ
(c)
2,0,∆2,0
}
of size B1. Given each
training response rate M 1, simulate B
′
1 samples under H1 and utilize the DNN from Algorithm 1
to compute their posterior probabilities at “S = FS(M ; “φ). The critical value c1 is computed as
the upper α quantile of “S1 in “S. Train a DNN to obtain the mapping function ĉ1 = F1(M 1; “φ1).
2. Under H2 in (5), train another DNN ĉ2 = F2(M 2; “φ2) to estimate c2 based on M 2 ={
ψ
(c)
1,0,∆1,0, ψ
(c,t)
2,0
}
of training data size B2 and null data size B
′
2.
3. Under H12 in (6), the training input data is M 12 =
{
ψ
(c,t)
1,0 , ψ
(c,t)
2,0
}
. The critical value c12 is
computed by solving a non-linear equation in (6) based on “S1 and “S2 of size B′12. The fitted DNN
is denoted as ĉ12 = F12(M 12; “φ12).
Compute critical values based on observed data in the current trial
{
R
(c)
1,0, R
(c)
2,0, R
(t)
1,0, R
(t)
2,0
}
4. Construct null data under (4) asM ′1 =
[{
R
(c)
1,0 +R
(t)
1,0
}
/
{
n
(c)
0 + n
(t)
0
}
, R
(c)
2,0/n
(c)
0 , R
(t)
2,0/n
(t)
0 −R(c)2,0/n(c)0
]
,
and calculate the critical value ĉ1 = F1(M
′
1;
“φ1).
5. Construct null data under (5) asM ′2 =
[
R
(c)
1,0/n
(c)
0 , R
(t)
1,0/n
(t)
0 −R(c)1,0/n(c)0 ,
{
R
(c)
2,0 +R
(t)
2,0
}
/(n
(c)
0 + n
(t)
0 )
]
,
and calculate the critical value ĉ2 = F2(M
′
2;
“φ2).
6. Construct null data under (6) asM ′12 =
[{
R
(c)
1,0 +R
(t)
1,0
}
/(n
(c)
0 + n
(t)
0 ),
{
R
(c)
2,0 +R
(t)
2,0
}
/(n
(c)
0 + n
(t)
0 )
]
,
and calculate the critical value ĉ12 = F12(M
′
12;
“φ12).
7. The final critical value is computed at c˜1 = max(ĉ1, ĉ12) for rejecting null hypothesis H1 with“S1 > c˜1, and c˜2 = max(ĉ2, ĉ12) with “S2 > c˜2 for H2.
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4 Simulation studies
In this section, we conduct simulation studies to evaluate the performance of our proposed method,
and compare it with the Meta-Analytic-Prior (MAP) approach (Neuenschwander et al., 2010; Schmidli
et al., 2014). Suppose that there are two endpoints (I = 2) to be evaluated in a randomized clinical
trial comparing a treatment versus placebo with equal sample size n
(c)
0 = n
(t)
0 = 150. The control
information is also available in J = 6 historical studies with sample sizes 100, 100, 200, 200, 300, and
300, with the response rates 0.4 and 0.3 for the two endpoints. We consider FWER to be controlled
at a one-sided level α = 0.05.
In this section we consider historical control data as in Table 1. The number of responders R
(c)
i,j
for endpoint i, i = 1, 2, study j, j = 1, · · · , 6 is simulated from a binomial distribution with rate 0.4
for endpoint i = 1 and 0.3 for endpoint i = 2. The empirical correlation of estimated response rate
R
(c)
i,j /n
(c)
j between two endpoints is 0.01. Additional simulation studies with an empirical correlation
around 0.5 are conducted in the Supplemental Materials to demonstrate consistent findings.
j 1 2 3 4 5 6
n
(c)
j 100 100 200 200 300 300
R
(c)
1,j 33 41 78 81 115 113
R
(c)
2,j 31 28 69 68 94 97
Table 1: Control data from J = 6 historical studies.
To implement our DNN-based method, we first approximate the posterior distribution S in
(3) based on Algorithm 1 with training data size B = 8, 000. Its training input data M ={
R
(c)
1,0, R
(c)
2,0, R
(t)
1,0, R
(t)
2,0
}
are drawn from binomial distributions with rates
{
ψ
(c)
1,0, ψ
(c)
2,0, ψ
(t)
1,0, ψ
(t)
2,0
}
, which
are further simulated from the following 4 patterns with equal size B/4 = 2, 000,
1. ψ
(c)
1,0 ∼ Unif(0.2, 0.7); ψ(c)2,0 ∼ Unif(0.1, 0.6); ∆1,0 = 0; ∆2,0 = 0,
2. ψ
(c)
1,0 ∼ Unif(0.2, 0.7); ψ(c)2,0 ∼ Unif(0.1, 0.6); ∆1,0 ∼ Unif(−0.1, 0.2); ∆2,0 = 0,
3. ψ
(c)
1,0 ∼ Unif(0.2, 0.7); ψ(c)2,0 ∼ Unif(0.1, 0.6); ∆1,0 = 0; ∆2,0 ∼ Unif(−0.1, 0.2),
4. ψ
(c)
1,0 ∼ Unif(0.2, 0.7); ψ(c)2,0 ∼ Unif(0.1, 0.6); ∆1,0 ∼ Unif(−0.1, 0.2); ∆2,0 ∼ Unif(−0.1, 0.2),
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where Unif denotes the Uniform distribution, and the treatment response rates are calculated at
ψ
(t)
i,0 = ψ
(c)
i,0 + ∆i,0 for i = 1, 2. Next we obtain posterior samples of ψ
(c)
i,0 from model (2) based on
the Markov chain Monte Carlo (MCMC) method implemented by the R package R2jags (Su and
Yajima, 2015). We put a vague prior on θ as a normal distribution with mean zero and precision
0.01, and a InverseWishart(Σ0, k) prior for Σ with Σ0 as a unit diagonal matrix and k = I+ 1. The
convergence of the MCMC algorithm is checked by the criteria of “R < 1.01 among 3 chains, where “R
is the ratio of between-chain versus within-chain variability (Gelman et al., 1992; Berry et al., 2010).
The posterior distribution of ψ
(t)
i,0 is a beta distribution with a non-informative beta prior ai = bi = 1
based on the Beta-Binomial conjugate model in (1). Our posterior probability Si in (3) is evaluated
by 10, 000 posterior samples with θi = 0. In Step 2, we choose a DNN structure with 2 layers, 60
nodes per layer by cross validation with validation MSE less than 10−3. The batch size is 100, and
the number of training epochs is 1, 000 with dropout rate 0.1. From the final fitting at Step 3, we
obtain DNN “S = FS(M ; “φ) to predict S in (3).
In Algorithm 2 of approximating the critical values, we simulate B1 = B2 = B12 = 2, 000 datasets
to reflect patterns of H1 in (4), H2 in (5) and H12 in (6),
1. ψ
(c,t)
1,0 ∼ Unif(0.2, 0.7); ψ(c)2,0 ∼ Unif(0.1, 0.6); ∆2,0 ∼ Unif(−0.1, 0.2); ψ(t)2,0 = ψ(c)2,0 + ∆2,0,
2. ψ
(c)
1,0 ∼ Unif(0.2, 0.7); ∆1,0 ∼ Unif(−0.1, 0.2); ψ(t)1,0 = ψ(c)1,0 + ∆1,0; ψ(c,t)2,0 ∼ Unif(0.1, 0.6),
3. ψ
(c,t)
1,0 ∼ Unif(0.2, 0.7); ψ(c,t)2,0 ∼ Unif(0.1, 0.6).
The number of iterations of calculating critical values are B′1 = B
′
2 = B
′
12 = 100, 000. The DNN
structure is selected at 3 layers with 50 nodes per layer by cross-validation.
We implement the Meta-Analytic-Predictive (MAP) priors (Neuenschwander et al., 2010) and two
robust MAP priors with a weight of w = 50% and w = 80% non-informative component (Schmidli
et al., 2014) by the R package RBesT (Weber, 2020). These methods handle data from each endpoint
separately, instead of modeling them jointly as in our model (2). The setup follows their default
settings with a weakly informative Half-Normal (0, 1) prior on the standard deviation of the logit of
the response rate (Weber et al., 2019). Hypothesis testing is also based on posterior probabilities Si,
but the critical values c˜i are chosen by a grid search method to control validation type I error rates
not exceeding α = 0.05 within a certain range of null response rates in the following Table 2.
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In Table 2, we first evaluate the error rates of falsely rejecting H12, H1 or H2 under the global null
hypothesis where ∆1,0 = ∆2,0 = 0. Our proposed method has a relatively accurate control on three
error rates at α = 0.05 across three scenarios with varying ψ
(c)
1,0 and ψ
(c)
2,0. The constant critical values
of MAP and two robust MAPs are chosen at 0.9975, 0.992, and 0.986, respectively, to ensure FWER
not exceeding α under all three cases. The “worst case scenario” is ψ
(c)
1,0 = 0.5 and ψ
(c)
2,0 = 0.4, where
the probability of rejecting H12 is approximately 0.05. This choice of critical values essentially leads
to conservative error rates in other cases and a potential power loss as evaluated later. Under a single
null hypothesis where only a single ∆i is equal to zero, the error rate happens when this particular
true null hypothesis is erroneously rejected. All methods control this error rate well below α. When
it comes to alternative hypotheses, our method has a higher power of rejecting each elementary null
hypothesis, and a higher power of rejecting at least one of them than MAP and two RMAPs under
ψ
(c)
1,0 = 0.3, ψ
(c)
2,0 = 0.2 and ψ
(c)
1,0 = 0.4, ψ
(c)
2,0 = 0.3. This is mainly due to the conservative type I
error of using a constant critical value for MAP and RMAPs. When response rates are higher at
ψ
(c)
1,0 = 0.5, ψ
(c)
2,0 = 0.4, MAP usually has the best power performance, followed by our DNN method,
and then two RMAPs. The number of simulation iterations in validation is 100, 000.
Table 3 presents the bias and Table 4 shows the root of mean squared error (RMSE) of posterior
means of ψ
(c)
1,0 and ψ
(c)
2,0. In scenarios where the current control rates and historical rates are consistent
at 0.4 for the first endpoint and 0.3 for the second endpoint, all methods have small biases, and MAP
has the smallest RMSE. Under cases with prior-data conflict, DNN and two RMAPs have better
bias than MAP, and moreover DNN has the smallest RMSE. The overall conclusion is that our DNN
based method enjoys the robustness of RMAP under prior-data conflict, and preserves power by
modeling critical values.
Figure 2 shows the approximation errors of DNN in estimating posterior means of ψ
(c)
1,0 and ψ
(c)
2,0,
and posterior probabilities S1 and S2 in (3) from B = 8, 000 training data. The MSE from DNN
training is approximately 0.001. Errors are relatively larger in approximating S1 and S2 from (3),
because their training labels have more randomness in the Monte Carlo estimates as compared with
the empirical posterior means of ψ
(c)
1,0 and ψ
(c)
2,0.
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DNN MAP RMAP with w = 50% RMAP with w = 80%
ψ
(c)
1,0
ψ
(c)
2,0
∆1,0 ∆2,0 H12 H1 H2 H12 H1 H2 H12 H1 H2 H12 H1 H2
Global null hypothesis
0.3 0.2 0 0 4.3% 3.0% 1.4% <0.1% <0.1% <0.1% 0.9% 0.3% 0.6% 2.2% 1.0% 1.2%
0.4 0.3 4.9% 2.8% 2.2% 0.3% 0.3% <0.1% 1.0% 0.8% 0.2% 2.0% 1.3% 0.7%
0.5 0.4 5.0% 3.4% 1.6% 5.4% 3.1% 2.3% 5.5% 2.7% 2.8% 5.2% 2.4% 2.9%
Single null hypothesis
0.4 0.3 0.1 0 47.0% 46.2% 1.6% 29.6% 29.6% <0.1% 39.7% 39.6% 0.2% 41.1% 40.7% 0.7%
0.4 0.3 0 0.1 44.6% 2.5% 43.0% 16.3% 0.2% 16.1% 29.2% 0.8% 28.7% 36.7% 1.3% 35.9%
Alternative hypothesis
0.3 0.2 0.1 0.1 72.2% 47.1% 46.9% 6.3% 3.2% 3.2% 32.0% 13.8% 21.1% 51.1% 25.1% 34.7%
0.12 0.12 85.5% 60.6% 62.3% 13.4% 7.5% 6.4% 48.1% 24.2% 31.5% 67.4% 37.6% 47.8%
0.4 0.3 0.1 0.1 66.3% 45.2% 38.1% 42.4% 30.5% 17.2% 57.5% 39.6% 29.7% 62.4% 40.7% 36.5%
0.12 0.12 80.3% 59.1% 51.6% 63.8% 46.6% 32.2% 76.2% 55.3% 46.6% 79.0% 55.3% 53.0%
0.5 0.4 0.1 0.1 65.9% 48.5% 34.0% 67.9% 43.1% 43.6% 60.1% 33.6% 39.9% 61.1% 35.5% 39.7%
0.12 0.12 80.2% 62.7% 47.4% 83.4% 60.6% 57.7% 74.0% 45.8% 52.0% 75.4% 48.8% 52.0%
Table 2: Type I error and power of DNN-based approach, MAP and RMAP.
Figure 2: Approximation error of DNN in estimating posterior means of ψ
(c)
1,0 and ψ
(c)
2,0, and posterior
probabilities S1 and S2 in (3).
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DNN MAP RMAP with w = 50% RMAP with w = 80%
ψ
(c)
1,0 ψ
(c)
2,0 ∆1,0 ∆2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0
Global null hypothesis
0.3 0.2 0 0 0.020 0.029 0.046 0.047 0.026 0.018 0.014 0.010
0.4 0.3 0.001 0.007 -0.011 0.015 -0.008 0.011 -0.004 0.008
0.5 0.4 -0.016 -0.011 -0.053 -0.044 -0.020 -0.024 -0.009 -0.012
Single null hypothesis
0.4 0.3 0.1 0 0.001 0.007 -0.010 0.015 -0.007 0.012 -0.004 0.008
0.4 0.3 0 0.1 0.001 0.007 -0.010 0.015 -0.007 0.012 -0.004 0.008
Alternative hypothesis
0.3 0.2 0.1 0.1 0.019 0.029 0.047 0.050 0.026 0.018 0.014 0.010
0.12 0.12 0.020 0.029 0.047 0.052 0.026 0.019 0.014 0.010
0.4 0.3 0.1 0.1 0.001 0.007 -0.010 0.015 -0.007 0.011 -0.004 0.008
0.12 0.12 0.001 0.008 -0.010 0.015 -0.007 0.012 -0.004 0.008
0.5 0.4 0.1 0.1 -0.016 -0.011 -0.053 -0.042 -0.020 -0.023 -0.009 -0.012
0.12 0.12 -0.016 -0.011 -0.056 -0.042 -0.020 -0.023 -0.009 -0.011
Table 3: Bias of posterior means ψ
(c)
1,0 and ψ
(c)
2,0 in DNN, MAP and RMAP.
5 A case study
We design a generic randomized clinical trial evaluating the efficacy of a study drug versus an active
comparator secukinumab 300 mg (Langley et al., 2014) in patients with moderate-to-severe plaque
psoriasis with equal sample size per group n
(c)
0 = n
(t)
0 = 200. We consider the co-primary endpoints in
Langley et al. (2014): the proportion of patients achieving a reduction of 75% or more from baseline
in the psoriasis area-and-severity index score (PASI 75) and the proportion of patients achieving a
score of 0 (clear) or 1 (almost clear) on a 5-point modified investigators global assessment (MIGA
0/1) at week 12. The control information is available in J = 3 historical studies: ERASURE,
FIXTURE (Langley et al., 2014) and JUNCTURE (Paul et al., 2015) with data summarized in
Table 5. The weighted observed response rates are approximately 0.80 and 0.65 for PASI 75 and
MIGA 0/1, respectively. We evaluate the performance of different methods on the following three
scenarios on response rates from the current trial:
1. Prior-data conflict scenario 1 (S1): ψ
(c)
1,0 = 0.7 and ψ
(c)
2,0 = 0.55,
2. Prior-data conflict scenario 2 (S2): ψ
(c)
1,0 = 0.9 and ψ
(c)
2,0 = 0.75,
3. Prior-data consistent scenario (S3): ψ
(c)
1,0 = 0.8 and ψ
(c)
2,0 = 0.65.
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DNN MAP RMAP with w = 50% RMAP with w = 80%
ψ
(c)
1,0 ψ
(c)
2,0 ∆1,0 ∆2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0 ψ
(c)
1,0 ψ
(c)
2,0
Global null hypothesis
0.3 0.2 0 0 0.037 0.039 0.053 0.061 0.047 0.046 0.043 0.039
0.4 0.3 0.031 0.031 0.017 0.020 0.023 0.024 0.029 0.029
0.5 0.4 0.038 0.036 0.066 0.052 0.054 0.048 0.047 0.044
Single null hypothesis
0.4 0.3 0.1 0 0.032 0.031 0.017 0.020 0.023 0.024 0.029 0.029
0.4 0.3 0 0.1 0.031 0.031 0.017 0.021 0.023 0.024 0.029 0.029
Alternative hypothesis
0.3 0.2 0.1 0.1 0.037 0.039 0.054 0.060 0.048 0.045 0.043 0.039
0.12 0.12 0.037 0.039 0.054 0.062 0.048 0.046 0.043 0.039
0.4 0.3 0.1 0.1 0.031 0.031 0.017 0.020 0.023 0.024 0.029 0.029
0.12 0.12 0.031 0.031 0.018 0.020 0.023 0.023 0.029 0.028
0.5 0.4 0.1 0.1 0.038 0.036 0.067 0.052 0.054 0.048 0.047 0.044
0.12 0.12 0.038 0.036 0.066 0.051 0.054 0.047 0.047 0.044
Table 4: RMSE of posterior means ψ
(c)
1,0 and ψ
(c)
2,0 in DNN, MAP and RMAP.
Historical study ERASURE FIXTURE JUNCTURE
n
(c)
j 245 323 60
R
(c)
1,j of PASI 75 200 249 52
R
(c)
2,j of MIGA 0/1 160 202 44
Table 5: Data of the active comparator secukinumab 300 mg in J = 3 historical studies.
When generating training data in our method, we consider the range of ψ
(c)
1,0 as 0.65 to 0.95, the
range of ψ
(c)
2,0 as 0.5 to 0.8, and the ranges of ∆1,0 and ∆2,0 as −0.1 to 0.1. The constant critical values
in MAP, RMAP with w = 50%, and RMAP with w = 80% are 0.987, 0.984, and 0.980, respectively,
to protect maximum validation type I error rates not exceeding α = 0.05 under three scenarios S1,
S2, and S3. Other parameter setups are the same as Section 4.
In terms of power, our DNN-based method has a higher probability of rejecting at least one null
hypothesis (Figure 3a) and of rejecting the first null hypothesis (Figure 3b) than MAP and two
RMAPs, but is slightly less powerful for rejecting the second null hypothesis under scenario S2. The
RMAP methods demonstrate the smallest absolute bias for the posterior means ψ
(c)
1,0 (Figure 4a)
and ψ
(c)
1,0 (Figure 4b) in general. Our method has the smallest RMSE under two prior-data conflict
scenarios, but the largest one under the prior-data consistent scenario. Therefore, our proposed
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method has satisfactory RMSE under prior-data conflicts, and preserves power by estimating critical
values with DNN.
6 Concluding remarks
In this article, we construct a prospective DNN-based algorithm from the Bayesian hierarchical model
to synthesize control information from multiple endpoints. Our two-stage method first approximates
posterior probabilities and then estimates critical values. The resulting pre-trained decision functions
can be locked in files before initiation of the current trial to ensure study integrity, which is appealing
to regulatory agencies.
Our DNN-based prospective algorithm can also save computational time. Taking the case study
in Section 5 for illustration, there are 12 setups (4 magnitudes of treatment effect × 3 scenarios) in
total and 100, 000 validation iterations per setup. As shown in Table 6, it takes approximately 32
hours for DNN to conduct the computation, while over 700 hours for the MCMC method. The main
saving is due to that DNN only requires 8, 000 MCMC samplings to build approximating function in
Algorithm 1 and therefore the validation is really fast. On the contrary, traditional approach needs
to conduct posterior sampling for every iteration (1, 200, 000 in total) in validation.
Method Algorithm 1 Algorithm 2 Validation Total time
DNN 5.12 26.67 0.04 31.83
MCMC - - 768 768
Table 6: Computational time (in hour) of DNN and MCMC in the case study.
Another important contribution of our work is to model the critical values by DNN to control
FWER. A common practice is to choose the cutoff value by a grid-search method to control type I
errors in validation within a certain range of the null space. Simulations show a moderate power gain
of our proposed method, especially when the constant critical value has a conservative error rate. To
accommodate approximation errors, a smaller working significance level can be utilized to control
validated type I error rates strictly no larger than the nominal level, if necessary. Our framework
can be broadly generalized to other types of Bayesian designs where the critical value is not available
analytically in finite samples.
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(a) Power of rejecting at least one null hypothesis.
(b) Power of rejecting the first null hypothesis.
(c) Power of rejecting the second null hypothesis.
Figure 3: Power performance of DNN, MAP and two RMAPs.
17
(a) Absolute bias of the posterior mean ψ
(c)
1,0.
(b) Absolute bias of the posterior mean ψ
(c)
2,0.
Figure 4: Absolute bias of posterior means ψ
(c)
1,0 and ψ
(c)
2,0 in DNN, MAP and two RMAPs.
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(a) RMSE of the posterior mean ψ
(c)
1,0.
(b) RMSE of the posterior mean ψ
(c)
2,0.
Figure 5: RMSE of posterior means ψ
(c)
1,0 and ψ
(c)
2,0 in DNN, MAP and two RMAPs.
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